Thermo Fisher Scientific (TMO) stock price, revenue, and financials

Thermo Fisher Scientific market cap is $189.1 b, and annual revenue was $25.54 b in FY 2019

$189.1 B

TMO Mkt cap, 03-Dec-2020

$8.5 B

Thermo Fisher Scientific Revenue Q3, 2020
Thermo Fisher Scientific Gross profit (Q3, 2020)4.3 B
Thermo Fisher Scientific Gross profit margin (Q3, 2020), %50.8%
Thermo Fisher Scientific Net income (Q3, 2020)1.9 B
Thermo Fisher Scientific EBIT (Q3, 2020)2.4 B
Thermo Fisher Scientific Cash, 26-Sept-20207.5 B
Thermo Fisher Scientific EV202.7 B

Thermo Fisher Scientific Revenue

Thermo Fisher Scientific revenue was $25.54 b in FY, 2019 which is a 4.9% year over year increase from the previous period.

Embed Graph

Thermo Fisher Scientific Revenue Breakdown

Embed Graph

Thermo Fisher Scientific revenue breakdown by business segment: 39.7% from Laboratory Products and Services, 13.9% from Specialty Diagnostics, 20.7% from Analytical Instruments and 25.7% from Life Sciences Solutions

Thermo Fisher Scientific revenue breakdown by geographic segment: 10.8% from China, 48.4% from United States and 40.8% from Other

Thermo Fisher Scientific Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

20.9b24.4b25.5b

Revenue growth, %

14%16%5%

Cost of goods sold

11.5b13.5b14.2b

Gross profit

9.4b10.9b11.3b

Gross profit Margin, %

45%45%44%

R&D expense

888.0m967.0m1.0b

General and administrative expense

5.5b6.1b6.1b

Operating expense total

6.5b10.9b7.1b

EBIT

3.0b3.8b4.6b

EBIT margin, %

14%16%18%

Interest expense

676.0m

Interest income

224.0m

Pre tax profit

2.4b3.3b4.1b

Income tax expense

201.0m324.0m374.0m

Net Income

2.2b2.9b3.7b

EPS

5.67.29.2

Thermo Fisher Scientific Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

1.3b2.1b2.4b

Accounts Receivable

3.9b4.1b4.3b

Inventories

3.0b3.0b3.4b

Current Assets

9.4b10.6b11.9b

PP&E

4.0b4.2b4.7b

Goodwill

25.3b25.3b25.7b

Total Assets

56.7b56.2b58.4b

Accounts Payable

1.4b1.6b1.9b

Short-term debt

2.1b1.3b676.0m

Current Liabilities

7.0b6.1b6.2b

Long-term debt

18.9b17.7b17.1b

Non-Current Liabilities

24.2b22.5b22.5b

Total Debt

21.0b19.0b17.8b

Total Liabilities

31.3b28.6b28.7b

Common Stock

428.0m432.0m434.0m

Additional Paid-in Capital

14.2b14.6b15.1b

Retained Earnings

15.9b18.7b22.1b

Total Equity

25.4b27.6b29.7b

Debt to Equity Ratio

0.8 x0.7 x0.6 x

Debt to Assets Ratio

0.4 x0.3 x0.3 x

Financial Leverage

2.2 x2 x2 x

Thermo Fisher Scientific Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

2.2b2.9b3.7b

Depreciation and Amortization

2.0b2.3b2.3b

Accounts Receivable

(362.0m)(366.0m)(225.0m)

Inventories

(81.0m)(324.0m)(458.0m)

Accounts Payable

274.0m201.0m266.0m

Cash From Operating Activities

4.0b4.5b5.0b

Purchases of PP&E

(508.0m)(758.0m)(926.0m)

Cash From Investing Activities

(7.7b)(1.3b)(1.5b)

Long-term Borrowings

(11.8b)(2.1b)(6.4b)

Dividends Paid

(237.0m)(266.0m)(297.0m)

Cash From Financing Activities

3.9b(2.2b)(3.1b)

Net Change in Cash

550.0m756.0m305.0m

Thermo Fisher Scientific Ratios

USDFY, 2017

EV/EBIT

32.3 x

EV/CFO

23.9 x

Revenue/Employee

298.8k

Debt/Equity

0.8 x

Debt/Assets

0.4 x

Financial Leverage

2.2 x

P/E Ratio

33.9

Thermo Fisher Scientific Operating Metrics

Thermo Fisher Scientific's Customers was reported to be 400 k in FY, 2019. Thermo Fisher Scientific's Backlog was reported to be $7.8b in FY, 2019.
FY, 2016FY, 2017FY, 2018FY, 2019Mar, 2020

Backlog

$4.46 b$5.09 b$7.77 b

Backlog (Analytical Instruments)

$2.05 b$2.24 b$2.20 b

Backlog (Laboratory Products and Services)

$1.68 b$2.06 b$4.58 b

Backlog (Life Sciences Solutions)

$594 m$647 m$893 m

Backlog (Specialty Diagnostics)

$158 m$187 m$172 m

Brands

6

Customers

400 k400 k400 k400 k

Thermo Fisher Scientific Sustainability Metrics

 FY, 2018

Сorporate Сontributions

$1.80 m

Waste Diverted from Landfills

3.20 k tons

Volunteer Hours

107.14 k

Thermo Fisher Scientific Human Capital

Thermo Fisher Scientific's employees are reported to be approximately 40% female and 60% male.

Gender

Y, 2019
Male58.9 %
Female39.5 %
Other1.5 %